Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial

EuroIntervention 2016;12:e235-e243 published online e-edition June 2016. DOI: 10.4244/EIJV12I2A37

Alec Vahanian
Alec Vahanian1*, MD; Marina Urena1, MD; Thomas Walther2, MD; Hendrik Treede3, MD; Olaf Wendler4, MD; Thierry Lefèvre5, MD; Mark S. Spence6, MD; Simon Redwood7, MD; Philipp Kahlert8, MD; Josep Rodes-Cabau9, MD; Jonathon Leipsic10, MD; John Webb10, MD
1. Bichat Claude Bernard Hospital-Paris VII University, Paris, France; 2. Kerckhoff Clinic, Bad Nauheim, Germany; 3. University Clinics Eppendorf, Hamburg, Germany; 4. King’s College Hospital, London, United Kingdom; 5. Institut Hospitalier Jacques Cartie

Aims: This study sought to investigate outcomes of transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 transcatheter heart valve (THV) in patients at intermediate risk for su

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

new-generation devicespacemakerparavalvular aortic regurgitationsapien 3transcatheter aortic valve implantation
Interventions for valvular diseaseTAVITools, devices and techniques
Read next article
Transapical mitral valve implantation after unclipping of a MitraClip: a glimpse into the future and treatment considerations in mitral regurgitation

Latest news